• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    IsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum "Homi" Shamir to its Board of Directors

    8/23/22 7:00:00 AM ET
    $CCTS
    $ISO
    $MDWD
    $SSKN
    Blank Checks
    Finance
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CCTS alert in real time by email

    BRANFORD, Conn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO) ("IsoPlexis"), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors as a Class II director.

    Mr. Shamir was most recently the Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. in 2021. Additionally, Mr. Shamir has served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien (now Medtronic) in 2014. Mr. Shamir currently serves on the Board of Directors of Strata Skin Sciences (NASDAQ:SSKN); and as Chairman of the Boards of Mediwound (NASDAQ:MDWD) and Cactus Acquisition Corp. (NASDAQ:CCTS). Mr. Shamir will serve on the Compensation and Nominating and Governance Committees.

    "On behalf of IsoPlexis's shareholders and Board, I would like to welcome Homi to our Board. We believe his insights into scaling large businesses in the life science, diagnostics, and device fields will be invaluable as we take the next stage of our journey," said Sean Mackay, Chief Executive Officer.   

    "I am honored to join the Board of Directors of IsoPlexis, an innovative lab tools company with high resolution technologies yet lab-friendly workflows, as they empower a wider range of labs worldwide," said Mr. Shamir. "I look forward to partnering with the Company's talented leadership team as they continue to further advance their suite of products to expand into larger markets with their applications, while simplifying and speeding up critical work for customers."

    In addition to adding Mr. Shamir, the Board of Directors also accepted the resignations of Siddhartha Kadia, Ph.D. and Michael Egholm, Ph.D. "We also wish to thank Siddhartha and Michael for their invaluable service and contributions to IsoPlexis, including their guidance through our initial public offering. We wish the best for each of them as they lead their respective organizations", said Sean Mackay, Chief Executive Officer. The Board will continue to search for one more member, and expects to fill this opening prior to its next annual meeting, with the expectation to add gender diversity with such appointment.

    About IsoPlexis

    IsoPlexis is empowering labs, changing the course of human health.

    By leading the discovery and identification of how multi-functional immune cells communicate and respond, IsoPlexis assists researchers in understanding and predicting disease progression, treatment resistance and therapeutic efficacy.

    IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies by revenue and 78% of leading U.S. comprehensive cancer centers.

    Forward Looking Statements

    This press release contains "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies and other future conditions. Such forward-looking statements may include, without limitation, statements about future opportunities for us and our products and services, our future operations, financial or operating results, including our financial guidance, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions and other expectations and targets for future periods. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "predict," "project," "target," "potential," "seek," "will," "would," "could," "continuing," "forward," "should," "continue," "contemplate," "plan," and other words and terms of similar meaning. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. We caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes may differ materially from those made in or suggested by the forward-looking statements contained in this press release. In addition, even if our results of operations, financial condition and cash flows, and the development of the markets in which we operate, are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods. New factors emerge from time to time that may cause our business not to develop as we expect, and it is not possible for us to predict all of them.

    Factors that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, among others, the following: estimates of our addressable market, market growth, future revenue, expenses, capital requirements and our needs for additional financing; the implementation of our business model and strategic plans for our products and technologies; competitive companies and technologies and our industry; our ability to manage and grow our business by expanding our sales to existing customers or introducing our products to new customers; our ability to develop and commercialize new products; our ability to establish and maintain intellectual property protection for our products or avoid or defend claims of infringement; the performance of third party suppliers; our ability to hire and retain key personnel and to manage our future growth effectively; our ability to obtain additional financing in future offerings; the volatility of the trading price of our common stock; our expectations regarding use of proceeds from our initial public offering ("IPO"); the potential effects of government regulation; the impact of COVID-19 on our business; and our expectations about market trends. For a further discussion of these and other factors that could impact our future results, performance or transactions, see the section "Risk Factors" included in our Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 30, 2022, and our other subsequent filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. We qualify all of the forward-looking statements in this press release by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Investor Contact

    [email protected]

    Press Contact

    [email protected]



    Primary Logo

    Get the next $CCTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CCTS
    $ISO
    $MDWD
    $SSKN

    CompanyDatePrice TargetRatingAnalyst
    MediWound Ltd.
    $MDWD
    5/2/2025$25.00Buy
    Alliance Global Partners
    MediWound Ltd.
    $MDWD
    2/28/2025$39.00Buy
    Craig Hallum
    MediWound Ltd.
    $MDWD
    7/16/2024$25.00 → $30.00Buy
    Maxim Group
    MediWound Ltd.
    $MDWD
    12/22/2022$11.00Buy
    Maxim Group
    MediWound Ltd.
    $MDWD
    7/18/2022$7.00Outperform
    Oppenheimer
    IsoPlexis Corporation
    $ISO
    2/15/2022$17.00 → $12.00Overweight
    Morgan Stanley
    IsoPlexis Corporation
    $ISO
    1/27/2022$20.00 → $15.00Outperform
    SVB Leerink
    IsoPlexis Corporation
    $ISO
    11/19/2021$24.00Outperform
    Evercore ISI Group
    More analyst ratings

    $CCTS
    $ISO
    $MDWD
    $SSKN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

      VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We entered 2025 with strong execution across our clinical, commercial, and operational priorities, mainta

      5/21/25 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases

      HORSHAM, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to advancing dermatologic care through innovation, announces that the American Medical Association (AMA) CPT Editorial Panel, in its May, 2025 summary of panel actions (May 2025: CPT® Editorial Summary of Panel Actions | AMA) has accepted revision to CPT codes 96920-96922, expanding reimbursement eligibility for excimer laser treatments to include multiple inflammatory and auto-immune skin conditions beyond their original psoriasis indication. This change reflects over 20 years of clinical evidence and real-world use of STRATA's XTRAC®

      5/19/25 8:00:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring XTRAC® revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic marketAverage net revenue per dome

      5/14/25 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $CCTS
    $ISO
    $MDWD
    $SSKN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on MediWound with a new price target

      Alliance Global Partners initiated coverage of MediWound with a rating of Buy and set a new price target of $25.00

      5/2/25 8:15:09 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Craig Hallum initiated coverage on MediWound with a new price target

      Craig Hallum initiated coverage of MediWound with a rating of Buy and set a new price target of $39.00

      2/28/25 7:39:12 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Maxim Group reiterated coverage on MediWound with a new price target

      Maxim Group reiterated coverage of MediWound with a rating of Buy and set a new price target of $30.00 from $25.00 previously

      7/16/24 8:08:28 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $CCTS
    $ISO
    $MDWD
    $SSKN
    SEC Filings

    See more
    • SEC Form 6-K filed by MediWound Ltd.

      6-K - MediWound Ltd. (0001593984) (Filer)

      5/21/25 7:07:42 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Strata Skin Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      5/19/25 4:30:20 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by MediWound Ltd.

      6-K - MediWound Ltd. (0001593984) (Filer)

      5/15/25 4:35:05 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $CCTS
    $ISO
    $MDWD
    $SSKN
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

      Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

      11/28/23 8:30:00 AM ET
      $APYX
      $PDSB
      $SSKN
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

      YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound. "We are delighted to welcome Shmulik, a distinguished industry executive, to our team. Dr. Hess joins MediWound during a crucial phase of expansion as we diligently implement our global strategy. Given Shmulik's outstanding track record in international o

      11/21/23 7:00:00 AM ET
      $ENLV
      $MDWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

      YAVNE, Israel, and DENKENDORF, Germany, Nov. 08, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, and PolyMedics Innovations (PMI), an innovative biomaterials company specializing in effective wounds treatment, today announced an agreement for the promotion of NexoBrid® in Germany, Austria, Belgium, the Netherlands and Luxemburg. Feedback from key opinion leaders and customers indicates that NexoBrid, a non-surgical solution for eschar removal in burns, is a perfect complement to PMI's existing product line, including SUPRATHEL®, NovoSorb® BTM, and SUPRA SDRM®. Along wit

      11/8/23 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $CCTS
    $ISO
    $MDWD
    $SSKN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $CCTS
    $ISO
    $MDWD
    $SSKN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CCTS
    $ISO
    $MDWD
    $SSKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-10) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 08/15/2024. Application Category: BLA, Application Number: 761192, Application Classification:

      8/16/24 4:36:54 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (ORIG-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

      12/30/22 4:38:06 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

      12/29/22 1:11:07 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cactus Acquisition Corp. 1 Limited

      SC 13G/A - Cactus Acquisition Corp. 1 Ltd (0001865861) (Subject)

      11/15/24 2:15:30 PM ET
      $CCTS
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

      SC 13G/A - MediWound Ltd. (0001593984) (Subject)

      11/14/24 7:55:11 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cactus Acquisition Corp. 1 Limited

      SC 13G/A - Cactus Acquisition Corp. 1 Ltd (0001865861) (Subject)

      11/14/24 5:30:34 PM ET
      $CCTS
      Blank Checks
      Finance
    • SEC Form 4 filed by Chief Operating Officer Gov Shmuel

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:21:12 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Accounting Officer Gillings John T

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:14:28 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Rafaeli Dolev

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:09:40 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $CCTS
    $ISO
    $MDWD
    $SSKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Leblanc Jeff bought $50,000 worth of Class A ordinary shares (100,000 units at $0.50), increasing direct ownership by 286% to 135,000 units (SEC Form 4)

      4 - Cactus Acquisition Corp. 1 Ltd (0001865861) (Issuer)

      8/1/24 4:06:03 PM ET
      $CCTS
      Blank Checks
      Finance
    • Director Ridgway Adam John bought $15,000 worth of Class A ordinary shares (30,000 units at $0.50), increasing direct ownership by 86% to 65,000 units (SEC Form 4)

      4 - Cactus Acquisition Corp. 1 Ltd (0001865861) (Issuer)

      7/29/24 4:02:12 PM ET
      $CCTS
      Blank Checks
      Finance
    • Director Geiger Uri bought $723,999 worth of shares (230,573 units at $3.14) (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:08:57 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $CCTS
    $ISO
    $MDWD
    $SSKN
    Financials

    Live finance-specific insights

    See more
    • MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

      VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We entered 2025 with strong execution across our clinical, commercial, and operational priorities, mainta

      5/21/25 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring XTRAC® revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic marketAverage net revenue per dome

      5/14/25 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate Update

      HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2025 financial results on Wednesday, May 14, 2025 after the market close. STRATA management will subsequently host a conference call at 5:00 p.m. ET on Wednesday, May 14, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested pa

      5/7/25 8:15:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care